Drug Trial Radar · NCT05686096
A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435
Last checked: Nov 19, 2026Latest source record: May 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Jan 16, 2023
Primary completion
Apr 8, 2023
Study completion Apr 8, 2023
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the absorption, metabolism, excretion; and to evaluate the safety and tolerability of BMS-986435 in healthy male participants Participants will be admitted to the study site for 3 weeks.
Conditions
- Healthy Volunteers
Interventions
MYK-224Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed concentration (Cmax)Time frame: Up to 45 days
- Time to maximum observed concentration (Tmax)Time frame: Up to 45 days
- Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))Time frame: Up to 45 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Local Institution - 0001
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.